U.S. flag

An official website of the United States government

GTR Home > Tests > CDH1 - MLPA

Indication

This is a clinical test intended for Help: Diagnosis

Clinical summary

Help

A cancer of the prostate. [from HPO]

Clinical features

Help

Conditions tested

Target population

Help

Not provided

Clinical validity

Help

This panel should be performed in all individuals suspected of having an overlapping clinical phenotype. Confirmation of a clinical diagnosis through genetic testing can allow for genetic counseling and may direct medical management. Genetic counseling can provide a patient and/or family with the natural history of the condition, identify at-risk family members, provide reproductive risks as well as preconception/prenatal options, and allow for appropriate referral for patient support and/or resources.

Citations

Not provided

Clinical utility

Help

Not provided

Suggested reading

Practice guidelines

  • NICE, 2023
    UK NICE Guideline NG12, Suspected cancer: recognition and referral, 2023
  • NCCN, 2022
    NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer, Version 4.2022
  • NICE, 2021
    UK NICE Guideline NG131, Prostate cancer: diagnosis and management, 2021
  • NCCN, 2011
    NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.